Now, it’s worth noting Stock Advisor’s total average return is 991 % — a market-crushing outperformance compared to 196% for ...

The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential ...

Praxis Precision Medicines has won Food and Drug Administration breakthrough-therapy designation for its ulixacaltamide drug candidate for the treatment of patients with essential tremor.

The latest announcement is out from Praxis Home Retail Ltd. ( ($IN:PRAXIS) ). Praxis Home Retail Limited has announced the resignation of senior ...

Praxis Precision Medicines remains a Hold as valuation now reflects high expectations for ulixacaltamide and its epilepsy ...

Praxis Precision Medicines Inc (NASDAQ: PRAX) stock rose after FDA granted BTD for ulixacaltamide to treat essential tremor.

As of Monday, December 29, Praxis Precision Medicines, Inc.’s PRAX share price has surged by 15.27%, which has investors ...

Having already claimed a win for the phase 2 study of its seizure drug, Praxis Precision Medicines is hoping fresh efficacy data will form the backbone of an approval application for the sodium ...

Praxis Precision Medicines has recorded a midphase win in epilepsy, linking the high dose of PRAX-628 to a 100% complete response rate to clear the path for a larger study in the second half of the ...

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal ...

Praxis said it is on track for filing for FDA approval of ulixacaltamide in early 2026. Praxis shares were recently changing hands at $300.74, up nearly 13%. Write to Colin Kellaher at ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Praxis Precision Medicines, a clinical-stage, genetic neuroscience company, launched today with more than $100 million in financing since its inception from premier ...